Drug intelligence / Profile preview

SHRN1034

Development stage: Unknown
Lead developer: Shivanka Research
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration: Subcutaneous

Overview

SHRN1034 is a prodrug of fulvestrant designed to improve the bioavailability and efficacy of fulvestrant in the treatment of advanced estrogen receptor-positive (ER+)/HER2-negative metastatic breast cancer. The drug aims to offer better patient compliance through lower injection volume, thinner needle, less pain, and more convenient administration compared to standard fulvestrant formulations. It has demonstrated promising results in preclinical studies and is currently in Phase 1 clinical trials. The primary mechanism involves antagonism and degradation of the estrogen receptor, thereby inhibiting estrogen-driven tumor growth[1][4].

Other names: SHRN1034SHRN-1034SHRN 1034

Targets

ESR1 (ERα)

Beyond the preview

Go deeper on SHRN1034.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHRN1034.

Explore the full profile